Titleist Asset Management LLC Has $438,000 Position in Abbott Laboratories $ABT

Titleist Asset Management LLC reduced its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,302 shares of the healthcare product maker’s stock after selling 135 shares during the period. Titleist Asset Management LLC’s holdings in Abbott Laboratories were worth $438,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ABT. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories during the 1st quarter worth about $27,000. Abound Financial LLC acquired a new stake in Abbott Laboratories during the 1st quarter worth about $28,000. Elequin Capital LP acquired a new stake in Abbott Laboratories during the 1st quarter worth about $30,000. Wormser Freres Gestion acquired a new stake in Abbott Laboratories during the 4th quarter worth about $32,000. Finally, JCIC Asset Management Inc. acquired a new position in shares of Abbott Laboratories during the first quarter valued at about $32,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ABT has been the topic of several research reports. Royal Bank Of Canada upped their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Mizuho upped their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a report on Wednesday, July 16th. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. Evercore ISI upped their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Finally, Leerink Partners assumed coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They set a “market perform” rating and a $143.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $144.47.

Abbott Laboratories Stock Up 0.9%

Shares of NYSE ABT opened at $132.59 on Friday. The stock has a market capitalization of $230.76 billion, a P/E ratio of 16.61, a P/E/G ratio of 2.52 and a beta of 0.70. The company has a 50-day moving average price of $130.99 and a 200-day moving average price of $131.35. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the company earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were issued a $0.59 dividend. The ex-dividend date was Tuesday, July 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.